Analysts Confident In Acceleron Pharma's Drug Trial Outcomes By: Benzinga via Benzinga June 23, 2016 at 13:30 PM EDT Barclays reiterated its Overweight rating on Acceleron Pharma Inc (NASDAQ: XLRN) after a meeting with management reinforced key elements ... Read More >> Related Stocks: Acceleron Pharma Celgene Corp